Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: A Systematic Review and Recommendations of Cannabis use in Bipolar Disorder and Major Depressive Disorder.
Tourjman SV, Buck G, Jutras-Aswad D, Khullar A, McInerney S, Saraf G, Pinto JV, Potvin S, Poulin MJ, Frey BN, Kennedy SH, Lam RW, MacQueen G, Milev R, Parikh SV, Ravindran A, McIntyre RS, Schaffer A, Taylor VH, van Ameringen M, Yatham LN, Beaulieu S.
Can J Psychiatry. 2023 May;68(5):299-311. doi: 10.1177/07067437221099769. Epub 2022 Jun 16.
PMID:35711159
Status of Type II vs. Type I Bipolar Disorder: Systematic Review with Meta-Analyses.
No Little Feet: Managing Pseudocyesis in a Homeless, Acutely Manic Patient with Schizoaffective Disorder, Bipolar Type.
West T, Ajibade O, Fontanetta A, Munir S.
Case Rep Psychiatry. 2023 Dec 13;2023:2504871. doi: 10.1155/2023/2504871. eCollection 2023.
PMID:38125275
Cariprazine-induced mania: A case series report.
Pons-Cabrera MT, Palacios-Garrán R, Tardón-Senabre L, Fernández-Plaza T, Marco-Estrada O, Madero S, Anmella G, Colomer L, Druetta M, Giménez-Palomo A, Navarro-Cortés L, Sagué-Vilavella M, Sánchez-Sierra C, Verdolini N, Catalan R, Bioque M, Goikolea JM, Vieta E, Pacchiarotti I.
Bipolar Disord. 2022 Jun;24(4):457-460. doi: 10.1111/bdi.13156. Epub 2021 Nov 27.
PMID:34797609
Olanzapine versus haloperidol in schizoaffective disorder, bipolar type.
Tohen M, Zhang F, Keck PE, Feldman PD, Risser RC, Tran PV, Breier A.